Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Objective: To systematically evaluate the safety and efficacy of docetaxel plus S-1-based therapy in gastric cancer treatment.Methods: PubMed, Embase, The Cochrane Library, and Web of Science electronic databases were searched for randomized controlled trials on docetaxel plus S-1-based therapy in t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1242548/full |
| _version_ | 1797362463460556800 |
|---|---|
| author | Hui-Fen Lv Hui-Fen Lv Li-Feng Qin Rui-Zhi Ran Xue-Ping Jiang Fang-Yu Zhao Bo Li |
| author_facet | Hui-Fen Lv Hui-Fen Lv Li-Feng Qin Rui-Zhi Ran Xue-Ping Jiang Fang-Yu Zhao Bo Li |
| author_sort | Hui-Fen Lv |
| collection | DOAJ |
| description | Objective: To systematically evaluate the safety and efficacy of docetaxel plus S-1-based therapy in gastric cancer treatment.Methods: PubMed, Embase, The Cochrane Library, and Web of Science electronic databases were searched for randomized controlled trials on docetaxel plus S-1-based therapy in the treatment of gastric cancer from the establishment of the database to 1 September 2022. Relevant studies were included per pre-defined eligibility criteria, and two researchers independently screened and assessed the included literature using Review Manager v5. Outcome measures and statistics related with efficacy and safety profiles were extracted from the included studies, and Stata v15.1 was used for pooled analysis.Results: Objective response rate (odds ratio = 2.34, 95% CI = [1.32, 4.13], p = 0.003), relapse-free survival (HR = 0.68, 95% CI = [0.58, 0.79], p < 0.001), progression-free survival (HR = 0.81, 95% CI = [0.68, 0.96], p = 0.016), and overall survival (HR = 0.86, 95% CI = [0.79, 0.95], p = 0.002) of docetaxel plus S-1-based therapy (DS-based therapy) in gastric cancer treatment were better than those of the non-DS-based therapy. However, DS-based therapy was associated with increased risk of certain adverse drug effects, such as alopecia, leukopenia, and oral mucositis. Further studies are warranted to validate the efficacy superiority of DS-based versus non-DS-based regimens as per our trial sequential analysis findings.Conclusion: DS-based therapy significantly improves patients’ clinical outcomes in gastric cancer, albeit at the cost of increased toxicity. Further RCTs are needed to confirm the efficacy superiority of DS-based regimens. |
| first_indexed | 2024-03-08T16:07:19Z |
| format | Article |
| id | doaj.art-4d47ba9e41cc401ca3dae22197c13904 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T16:07:19Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4d47ba9e41cc401ca3dae22197c139042024-01-08T04:46:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-01-011410.3389/fphar.2023.12425481242548Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trialsHui-Fen Lv0Hui-Fen Lv1Li-Feng Qin2Rui-Zhi Ran3Xue-Ping Jiang4Fang-Yu Zhao5Bo Li6Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi, ChinaDepartment of Pharmacology, Health Science Center, Hubei Minzu University, Enshi, ChinaDepartment of Gastroenterology, Minda Hospital of Hubei Minzu University, Enshi, ChinaDepartment of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, ChinaDepartment of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, ChinaDepartment of Pathology, Health Science Center, Hubei Minzu University, Enshi, ChinaDepartment of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, ChinaObjective: To systematically evaluate the safety and efficacy of docetaxel plus S-1-based therapy in gastric cancer treatment.Methods: PubMed, Embase, The Cochrane Library, and Web of Science electronic databases were searched for randomized controlled trials on docetaxel plus S-1-based therapy in the treatment of gastric cancer from the establishment of the database to 1 September 2022. Relevant studies were included per pre-defined eligibility criteria, and two researchers independently screened and assessed the included literature using Review Manager v5. Outcome measures and statistics related with efficacy and safety profiles were extracted from the included studies, and Stata v15.1 was used for pooled analysis.Results: Objective response rate (odds ratio = 2.34, 95% CI = [1.32, 4.13], p = 0.003), relapse-free survival (HR = 0.68, 95% CI = [0.58, 0.79], p < 0.001), progression-free survival (HR = 0.81, 95% CI = [0.68, 0.96], p = 0.016), and overall survival (HR = 0.86, 95% CI = [0.79, 0.95], p = 0.002) of docetaxel plus S-1-based therapy (DS-based therapy) in gastric cancer treatment were better than those of the non-DS-based therapy. However, DS-based therapy was associated with increased risk of certain adverse drug effects, such as alopecia, leukopenia, and oral mucositis. Further studies are warranted to validate the efficacy superiority of DS-based versus non-DS-based regimens as per our trial sequential analysis findings.Conclusion: DS-based therapy significantly improves patients’ clinical outcomes in gastric cancer, albeit at the cost of increased toxicity. Further RCTs are needed to confirm the efficacy superiority of DS-based regimens.https://www.frontiersin.org/articles/10.3389/fphar.2023.1242548/fullchemotherapyDS-based regimenmeta-analysisclinical outcomeadverse event |
| spellingShingle | Hui-Fen Lv Hui-Fen Lv Li-Feng Qin Rui-Zhi Ran Xue-Ping Jiang Fang-Yu Zhao Bo Li Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials Frontiers in Pharmacology chemotherapy DS-based regimen meta-analysis clinical outcome adverse event |
| title | Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials |
| title_full | Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials |
| title_fullStr | Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials |
| title_short | Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials |
| title_sort | efficacy and safety of docetaxel plus s 1 based therapy in gastric cancer a quantitative evidence synthesis of randomized controlled trials |
| topic | chemotherapy DS-based regimen meta-analysis clinical outcome adverse event |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1242548/full |
| work_keys_str_mv | AT huifenlv efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT huifenlv efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT lifengqin efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT ruizhiran efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT xuepingjiang efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT fangyuzhao efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials AT boli efficacyandsafetyofdocetaxelpluss1basedtherapyingastriccanceraquantitativeevidencesynthesisofrandomizedcontrolledtrials |